FDA approves the first treatment option for generalized pustular psoriasis flares in adults

More than half of patients treated with SPEVIGO® (spesolimab-sbzo) injection, for intravenous use showed no visible pustules one week after receiv...

Related Keywords

New York ,United States ,Prnewswire Boehringer Ingelheim ,Thomas Seck ,Carinne Brouillon ,Mark Lebwohl ,Chris Wahlers ,Boehringer Ingelheim Pharmaceuticals ,Ericj Waldman Department Of Dermatology ,Regulatory Affairs ,Drug Administration ,Boehringer Ingelheim ,Icahn School Of Medicine At Mount Sinai ,Animal Health ,Clinical Therapeutics ,Icahn School ,Mount Sinai ,Managing Directors ,Human Pharma ,Senior Vice President ,Ingelheim Immunology ,Pioneering Science ,Biopharmaceutical Contract ,